The cut off for positivity is still matter of debate, however, expression of BCL2 more or equal to 50% and MYC expression more or equal to 40% as originally reported is considered adequate.1 DELs have been associated with an inferior prognosis under RCHOP treatment.15,20–22 However, and despite the recognition of the adverse associated prognosis, the biology of DELs is still unclear; indeed, in the updated WHO this entity has not been assigned to a specific category and is grouped within DLBCL NOS. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.